Login to Your Account

Dicerna, Kyowa $1.4B Pact Called Largest Target-Based RNAi Deal

By Donna Young

Tuesday, January 5, 2010
In its first major deal, Dicerna Pharmaceuticals Inc. is partnering with Japanese biopharmaceutical firm Kyowa Hakko Kirin Co. Ltd. to discover, develop and commercialize drug delivery systems and siRNA medications using Dicerna's Dicer Substrate Technology for undisclosed oncology targets. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription